

March 20, 2023

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Growth Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8046
URL: <https://solasia.co.jp/en/>

SOLASIA HAS PARTNERED WITH WEP CLINICAL TO SUPPLY DARVIAS® [DARVIAS® Injection 135mg] UNDER A NAMED PATIENT PROGRAM

TOKYO, JAPAN, March 1, 2023 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") officially announced today that WEP Clinical LTD (a UK- & US-based company, hereinafter "WEP"), have commenced a Named Patient Program (NPP) for DARVIAS® Injection 135 mg, anti-tumor agents / Organoarsenic compound [generic name: darinaparsin] (hereinafter "DARVIAS®"), a treatment for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter "PTCL").

DARVIAS® is an anti-cancer agent with a novel mechanism of action, which was approved and launched in Japan in 2022 for relapsed or refractory PTCL.

The NPP is designed to ensure that physicians in Europe and other regions around the world, where DARVIAS® is not commercially available, can request DARVIAS® on behalf of individual patients who need a new treatment option in PTCL.

For physicians who are interested in further information on the DARVIAS® Named Patient Program, please contact: darviasnpp@wepclinical.com

Mr. Jas Khera, Managing Director of WEP Clinical, said:

"We are excited to partner with Solasia to help facilitate broader access to this important therapeutic treatment. Solasia has already achieved some important milestones with DARVIAS®, and the WEP Clinical team is looking forward to helping to make DARVIAS® available to patients in Europe and rest of the world having the need for this specific treatment."

Mr. Yoshihiro Arai, President and CEO of Solasia, made the following statement:

"Since its founding, we have been focusing on developing new treatment options that solve the quality of life for cancer patients. We are very pleased to have this opportunity to work with WEP Clinical to offer DARVIAS® as a new treatment option for PTCL in regions outside of Japan."

About WEP Clinical

At WEP Clinical, we are With Every Patient, as we believe every patient has the right to treatment. With this as our leading principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit www.wepclinical.com.

About Solasia Pharma K.K.

Solasia Pharma K.K. is a specialty pharmaceutical company, headquartered in Japan and focused on developing and commercializing oncology therapies and supportive care products in Japan, China, and other Asian countries. For more information, please visit <https://solasia.co.jp/en/>

About Peripheral T-Cell Lymphoma (PTCL)

PTCL is a type of malignant lymphoma that is broadly classified into Hodgkin's lymphoma and non-Hodgkin's lymphoma, and non-Hodgkin's lymphoma into B-cell lymphoma and T-cell lymphoma. There is no standard treatment for PTCL, and the National Comprehensive Cancer 2 Network (NCCN) guidelines recommend multiple-drug chemotherapy, including CHOP, as initial treatment, in addition to participation in clinical trials. In addition, the guidelines also recommend the use of combination chemotherapy such as CHOP for relapsed or refractory cases. The NCCN (National Comprehensive Cancer 2 Network) guideline recommends that patients with relapsed or refractory disease be treated with combination chemotherapy and recently approved drugs, as well as participation in clinical trials. PTCL is one of the diseases with high unmet medical needs.

Disclaimer:

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company's actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release is for informational purposes only and should not be considered as investment solicitation. Information with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice. We do not have any obligation to update or revise any information in this press release, and any update or revision may occur anytime without notice.